hit counter
argenx SE (ARGX) Stock News Sentiment & Price - Sentifly
ARGX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



argenx SE (ARGX)

Netherlands
Biotechnology
NASDAQ
ARGX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
ARGX Latest news
GlobeNewsWire
Neutral
argenx to Highlight Potential First-in-Class FcRn Antagonist Efgartigimod at Upcoming Neuromuscular Meetings
2021-10-08 01:00

Breda, the Netherlands – October 8 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancers, today announced the presentation of additional data from the Phase 3 ADAPT trial of efgartigimod for the treatment of generalized myasthenia gravis (gMG). The data will be presented at two upcoming neuromuscular meetings: the American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting on October 13-16, 2021 in Aurora, CO and the virtual Myasthenia Gravis Foundation of America Scientific Session (MGFA) on October 30, 2021.

GlobeNewsWire
Neutral
argenx to Present at Upcoming Investor Conferences
2021-09-03 01:00

September 3, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in several upcoming conferences:

GlobeNewsWire
Neutral
argenx Announces Validation of European Marketing Authorization Application for Efgartigimod in Generalized Myasthenia Gravis
2021-08-25 01:00

Breda, the Netherlands – August 2 5 , 2021 – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it has submitted, and the European Medicines Agency (EMA) has validated, the marketing authorization application (MAA) for the Company's investigational FcRn antagonist, efgartigimod, for the treatment of generalized myasthenia gravis (gMG). Validation of the MAA confirms that the application is sufficiently complete to begin the formal review process.

Seeking Alpha
Positive
argenx: R&D Day Goes Unnoticed
2021-08-23 11:22

argenx held an R&D day last month and it went largely unnoticed. The company outlined an ambitious 2025 vision for efgartigimod, ARGX-117, and its Immunology Innovation Program.

GlobeNewsWire
Neutral
argenx to Present at 2021 Wedbush PacGrow Virtual Healthcare Conference
2021-08-04 01:00

August 4, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that members of management will participate in a fireside chat at the 2021 Wedbush PacGrow Virtual Healthcare Conference on Wednesday, August 11, 2021 at 11:30 a.m. ET.

Seeking Alpha
Neutral
argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript
2021-08-01 04:31

argenx SE (ARGX) CEO Tim Van Hauwermeiren on Q2 2021 Results - Earnings Call Transcript

Benzinga
Negative
Recap: argenx Q2 Earnings
2021-07-29 07:24

Shares of argenx (NASDAQ:ARGX) decreased 4.8% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share rose 162.86% over the past year to $1.98, which may not compared to the estimate of ($3.63).

GlobeNewsWire
Neutral
argenx Reports Half Year 2021 Financial Results and Provides Second Quarter Business Update
2021-07-29 01:00

- Completion of enrollment expected by year-end for ADAPT-SC and ADVANCE (IV) trials of efgartigimod; topline data for both trials expected in first half of 2022

GlobeNewsWire
Neutral
argenx to Report Half Year 2021 Financial Results and Second Quarter Business Update on July 29, 2021
2021-07-22 01:00

July 22, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a conference call and audio webcast on Thursday, July 29, 2021 at 2:30 p.m. CET (8:30 a.m. ET) to discuss its half year 2021 financial results and provide a second quarter business update.

GlobeNewsWire
Neutral
argenx to Host Virtual R&D Day on July 20, 2021
2021-07-14 01:00

July 14, 2021 Breda, the Netherlands – argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer, today announced that it will host a virtual R&D Day on Tuesday, July 20, 2021 at 3:00 p.m. CET (9:00 a.m. ET) to highlight its ‘argenx 2025 vision' and provide an update of its immunology pipeline. The event will introduce the fifth and sixth indications for the Company's FcRn antagonist, efgartigimod, and will include Phase 1 data from its C2 inhibitor, ARGX-117.

Loading more news...